Stock of the Day

Abiomed (ABMD)

$381.02

$0.00 (0.0%)

Market Cap: $17.18B

About Abiomed

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients.

The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Abiomed Bull Case

Here are some ways that investors could benefit from investing in Abiomed, Inc.:

• The current stock price is around $720, indicating strong market interest and potential for growth.
• Abiomed, Inc. has a robust portfolio of innovative heart pump technologies, including the latest Impella devices, which are critical in treating heart failure.
• The company has recently updated the instructions for the Impella RP in a Class I recall, demonstrating a commitment to patient safety and regulatory compliance.
• As a subsidiary of Johnson & Johnson, Abiomed, Inc. benefits from the financial stability and resources of a larger parent company, which can support its growth initiatives.
• The global market for heart failure treatments is expanding, providing Abiomed, Inc. with significant opportunities for revenue growth in various regions, including Europe and Asia-Pacific.

Abiomed Bear Case

Investors should be bearish about investing in Abiomed, Inc. for these reasons:

• Recent recalls, such as the Class I recall for the Impella RP, may raise concerns about product reliability and could impact sales.
• The medical device industry is highly competitive, and Abiomed, Inc. faces pressure from other companies developing similar heart pump technologies.
• Regulatory challenges can lead to delays in product approvals and market entry, potentially affecting the company's growth trajectory.
• Market volatility can impact stock performance, and investors should be cautious of fluctuations in the healthcare sector.
• As a company focused on a niche market, Abiomed, Inc. may be more susceptible to economic downturns that affect healthcare spending.